<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760760</url>
  </required_header>
  <id_info>
    <org_study_id>PUFA-ATI1</org_study_id>
    <secondary_id>OeNB12735</secondary_id>
    <nct_id>NCT00760760</nct_id>
  </id_info>
  <brief_title>n-3 Polyunsaturated Fatty Acids in Obesity</brief_title>
  <acronym>PUFA-ATI</acronym>
  <official_title>Impact of n-3 Polyunsaturated Fatty Acids on Adipose Tissue Inflammation in Morbidly Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Bank of Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation in the adipose (fat) tissue is an important condition leading to metabolic
      derangements and cardiovascular disease in obese patients. n-3 polyunsaturated fatty acids
      exert anti-inflammatory effects and prevent adipose tissue inflammation in rodent obesity.
      This study tests the hypothesis that n-3 polyunsaturated fatty acids ameliorate adipose
      tissue inflammation in morbidly obese patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adipose tissue inflammation</measure>
    <time_frame>Eight weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic control</measure>
    <time_frame>Eight weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dependence of effects on Pparg polymorphisms</measure>
    <time_frame>Eight weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Adipose Tissue Inflammation</condition>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>n-3 PUFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)</intervention_name>
    <description>4g daily, 8 weeks</description>
    <arm_group_label>n-3 PUFA</arm_group_label>
    <other_name>OmacorÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control</intervention_name>
    <description>equivalent amount of fat as butter</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-diabetic morbidly obese patients (BMI &gt; 40 kg/m2) supposed to undergo bariatric
             surgery

          -  Age 20-65 yrs

        Exclusion Criteria:

          -  Acute illness within the last two week

          -  Known diabetes mellitus or current anti-diabetic medication

          -  Acquired immunodeficiency (HIV infection)

          -  Hepatitis or other significant liver disease

          -  Severe or untreated cardiovascular, renal, pulmonary disease

          -  Untreated or inadequately treated clinically significant thyroid disease

          -  Anemia

          -  Active malignant disease

          -  Inborn or acquired bleeding disorder including warfarin treatment

          -  Pregnancy or breast feeding

          -  Drug intolerability that prohibits the use of the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M Stulnig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Thomas M Stulnig</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

